

Access and Benefit Sharing of marine genetic resources

Dr. Thomas Vanagt (ABS-int)

28 March 2019



Criteria for balanced benefit-sharing

Elements to consider:


- Size and timing of benefits accrued by user(s)
- Cost and burden of benefit-sharing to the user
- Burden of benefit-sharing to the regulator – institutional cost
- Who are the beneficiaries?
- How many beneficiaries are there?
- Impact of benefit-sharing on the beneficiary
- Timing of the transaction

Why should we have a balanced BS
mgr?
Not only to ensure fair & equitable sharing of benefits (with beneficiaries), but also to promote the generation of benefits (through access to and utilisation of mgr) which can then be shared In order to balance BS, we need to consider a number of elements.




Biodiscovery pipeline

Funnel – many thousands of compounds enter at the discovery phase of the pipeline, with very few successfully developed into commercial products. The LENGTH of this pipeline (in years) varies according to target market; will be far longer for pharma (at least 10 years normally) compared to cosmetics, nutraceutical or ipd biotech.



Sampling in ABNJ



Scientific knowledge & data

Commercial

'Potential' value

Actual value



Mare geneticum

Requirements:

- Inclusivity of developing states
- Facilitated access for the scientific community
- Legal certainty, predictability and stability for industry
- Enforceability for the regulator

Inclusivity of developing (or EMERGING MGR) States in the access (through CB & TT) and utilization of MGR
A group of my colleagues have worked on a potential workable solution that fits these criteria and are published in the paper called 'Mare Geneticum'



Mare geneticum

Access:

- Online notification system: OPEN
- Free but conditional access
- Embargo period

Presenter

2019-04-03 10:27:50

Obligatory Prior Electronic Notification

as mentioned in the President's aid

Conditional access – not necessarily

some conditions/ requirements and

restrictions (e.g. deposit in collection?)

Embargo period – to enable scientists/

private sector to develop R&D results



Mare geneticum

Benefit-Sharing:


- Mandatory deposit of material in biorepositories
- Mandatory sharing of meta data and raw data (including GSD)
- Possibility of extending embargo period in return for a fee
- If monetary benefits are requested: at the point of commercialization, and not negotiated

But not necessarily mandatory sharing
'value-added' data (could be encouraged but not mandatory, otherwise risk deterring private sector)
If it is decided during negotiations that benefit-sharing should be requested, then this should be at the point of commercialization and it should also be




Biodiscovery pipeline and Benefit-sharing

Funnel – many thousands of compounds enter at the discovery phase of the pipeline, with very few successfully developed into commercial products. The LENGTH of this pipeline (in years) varies according to target market; will be far longer for pharma (at least 10 years normally) compared to cosmetics, nutraceuticals and biotech.



Sampling in ABNJ



Scientific knowledge & data

Commercial



Embargo period (fee)



Deposit in biorepository
Sharing of metadata

Sharing of MGR data

Monetary BS ?




Obligatory Prior Electronic Notification
as mentioned in the President's aid
Conditional access – not necessarily
some conditions/ requirements and
restrictions (e.g. deposit in collection?)
Embargo period – to enable scientists/
private sector to develop R&D results

TRACK & TRACE

ACTIVITY

BENEFIT SHARING



Thank you!

Contact: thomas.vanagt@abs-int.eu